Aldeyra Therapeutics (NASDAQ:ALDX) Stock Moves Up After The Positive News

August 4, 2021

Aldeyra Therapeutics (NASDAQ:ALDX) announces that the U.S. FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP), a group of rare genetic eye diseases. Shares up more than 6% premarket. There are no approved drug treatments for patients with RP, which is a disease affects an estimated 82,000-110,000 individuals in the United States. The FDA’s orphan drug designation program is designed…

Read More >>